Athira Pharma, Inc. — Director's Dealing 2022

May 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-05-20

Reporting Person: Romano Kelly A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-20	Stock Option (Right to Buy)	$8.93	A	13871	Acquired	2032-05-19	Common Stock (13871)	Direct

Footnotes

F1: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.